Do GLP-1 Injections Reduce Alcohol and Smoking Cravings?

It often begins with an ordinary moment. Someone in Leeds starts a weekly injection for weight management and, a few weeks later, pours their usual Friday-night wine. Half the glass remains untouched. Another person in Swansea notices that the cigarette after lunch no longer has the same pull. They were not trying to change either habit. It simply feels different.

Stories like these have travelled quickly through clinics, online forums and newspaper health pages. They have also reached scientists. GLP-1 medicines such as semaglutide are best known for diabetes and obesity, but researchers are now asking whether their effects reach beyond appetite for food and into the brain circuits involved in alcohol and nicotine craving.

In brief: early studies suggest GLP-1 medicines may make alcohol or cigarettes feel less compelling for some people. The evidence is stronger for reducing certain alcohol outcomes than it is for helping smokers quit. These injections are not currently approved UK treatments for alcohol dependence or smoking cessation, and they should not replace established care.

What does a change in craving actually feel like?

Craving is not always a dramatic, physical urge. It can be quieter than that: thinking about the bottle in the kitchen, planning the next cigarette, noticing every pub on the walk home or feeling that an evening has not properly begun until the first drink is poured.

People sometimes call this constant mental background activity “food noise” when describing obesity treatment. A similar phrase “alcohol noise” has appeared in personal accounts from GLP-1 users. The drink may still be available, but the repeated internal conversation about it becomes less insistent.

There are other descriptions too. Beer may taste oddly flat. A cigarette may be started and abandoned. A person might still visit the same pub in Newcastle with the same friends, yet find it easier to order a soft drink after one pint. These are observations rather than reliable predictions. Some people notice no change at all, while others feel nauseated and avoid alcohol simply because drinking makes them feel worse.

How could a diabetes medicine affect alcohol or nicotine?

GLP-1—glucagon-like peptide-1—is a hormone involved in blood-glucose regulation, digestion and satiety. Medicines that act on the GLP-1 receptor can slow gastric emptying and help the brain register fullness. Semaglutide is the active ingredient in Wegovy, Ozempic and Rybelsus, although these brands have different licensed uses and formulations.

The brain does not keep food, alcohol and nicotine in completely separate filing cabinets. All can interact with networks involved in motivation, learning and reward. GLP-1 receptors are present in brain regions that communicate with these networks, including pathways influenced by dopamine.

Animal studies suggest that activating GLP-1 receptors can reduce alcohol consumption and nicotine-seeking behaviour. In humans, researchers are examining several possible explanations:

Reduced reward: alcohol or nicotine may produce less of the anticipated satisfaction.
Weaker cue response: familiar triggers—the end of a shift, a certain friend or the first coffee—may provoke less wanting.
Greater general satiety: the sense of “enough” may extend beyond meals.
Physical effects: nausea, reflux or feeling full may make drinking temporarily unattractive.
Changed routine: weight loss, better mobility or closer medical follow-up may indirectly alter substance use.

No single explanation has been proven. It may turn out that several mechanisms operate together, and that the balance differs from person to person.

The alcohol evidence: promising, but still early

A small randomised clinical trial published in JAMA Psychiatry in 2025 provided the clearest prospective evidence so far. Researchers assigned 48 adults with alcohol use disorder to low-dose weekly semaglutide or placebo for nine weeks.

Semaglutide reduced the amount of alcohol consumed during a controlled laboratory session. It also reduced drinks per drinking day, weekly alcohol craving and heavy-drinking days relative to placebo. Those results matter because they move the subject beyond social-media anecdotes.

But the medicine did not improve every measure. It did not significantly change the average number of drinks per calendar day or the number of drinking days. Participants were not seeking treatment, the study was short and the group was small. Most were overweight or living with obesity. The trial therefore cannot tell us whether semaglutide produces lasting recovery in the wider population of people with alcohol dependence.

A nationwide Swedish registry study added another encouraging signal. Among people diagnosed with alcohol use disorder, periods of GLP-1 medicine use—particularly semaglutide—were associated with fewer alcohol-related hospital admissions. Registry studies are valuable, but they cannot remove every difference between people who receive a medicine and those who do not. Association is not the same as proof of treatment effect.

A new British study brings the question closer to home

In August 2026, NHS and university researchers announced a four-year, £2.7 million study investigating semaglutide in people living with alcohol dependence, obesity and alcohol-related liver disease. The work is being co-led by teams connected with the University of Plymouth, University Hospitals Plymouth, Nottingham University Hospitals and the NIHR Biomedical Research Centre in Nottingham.

This is an important UK development because alcohol-related liver disease is not an abstract laboratory outcome. It fills medical wards from Glasgow to London and affects families long before a hospital admission appears in official statistics. Obesity and alcohol-related harm can also occur together, creating difficult decisions about nutrition, liver health, cardiovascular risk and relapse prevention.

Why this UK research matters: a medicine that safely reduced drinking while improving weight and metabolic health could address several connected risks at once. That is the hope being tested—not a conclusion that has already been reached.

The study should not be reported as proof that Wegovy treats alcoholism. Its value lies in asking clinically useful questions in NHS patients and examining whether an apparent side effect can become a safe, deliberate treatment strategy.

What does the smoking research show?

Research into GLP-1 medicines and nicotine is less mature. A 2021 pilot study tested weekly exenatide alongside nicotine patches and counselling in smokers with prediabetes or overweight. The group receiving exenatide had better short-term abstinence, less craving and less post-cessation weight gain than the comparison group.

That combination is interesting because fear of gaining weight can discourage some smokers from attempting to quit. However, exenatide was added to nicotine replacement and behavioural support. The study does not show that a GLP-1 injection used alone is a dependable stop-smoking treatment.

A separate phase 2a semaglutide trial reported in 2026 involved only 24 adults who smoked daily and were not trying to stop. Semaglutide reduced reported cigarette craving and body weight, but it did not significantly reduce cigarettes smoked per day. The main laboratory outcomes—delaying smoking and the number of cigarettes smoked during the task—were not significant in the planned interaction analyses.

That result is a useful warning against turning “less craving” into “successful quitting”. A medicine might soften an urge without producing abstinence. To establish semaglutide as a smoking-cessation treatment, larger trials would need to recruit people who want to quit, combine the medicine appropriately with behavioural care, confirm abstinence biochemically and follow participants for many months.

What has been observed?	What can we reasonably conclude?
Some GLP-1 users spontaneously report drinking less.	This is a valuable signal, but personal experience cannot establish cause or predict who will respond.
A small semaglutide trial improved several alcohol outcomes.	Semaglutide deserves larger alcohol-use-disorder trials; it is not yet proven long-term treatment.
A small smoking trial found lower cigarette craving.	GLP-1 signalling may affect nicotine reward, but cigarettes per day did not significantly fall.
Weight may fall during GLP-1 treatment.	This could help people concerned about post-quit weight gain, but addiction treatment cannot be inferred from weight loss alone.
UK researchers are studying semaglutide and alcohol-related liver disease.	The question is now being tested in an NHS-relevant population; results must be awaited.

Could nausea explain the whole effect?

It is tempting to say that people drink less simply because semaglutide makes them feel sick. Nausea, vomiting, diarrhoea and constipation are recognised side effects, particularly while the dose is being increased. The NHS advises that it is best not to drink alcohol while taking semaglutide because alcohol can increase side effects such as nausea and vomiting.

Yet nausea probably does not explain everything. Researchers have recorded changes in craving and reward-related behaviour, and animal findings existed before widespread public enthusiasm for weight-loss injections. The honest answer is that physical discomfort, altered taste, fullness and central reward effects may overlap.

This distinction matters for treatment. Making someone too unwell to drink is neither a sophisticated nor necessarily safe answer to addiction. A useful medicine would need to reduce harmful behaviour with acceptable side effects and improve outcomes that matter to patients.

Craving is only one part of addiction

Imagine someone who drinks most evenings after a lonely commute from Birmingham into a quiet flat. Reducing the biological pull of alcohol could create breathing space, but it would not automatically change isolation, anxiety, habit or the social meaning of drinking. Similarly, reducing the reward from a cigarette does not remove a stressful workplace or teach somebody what to do during a ten-minute break.

Addiction treatment often works best when several layers are addressed:

physical dependence and safe withdrawal;
cravings and relapse-prevention medication;
mental health, trauma or chronic stress;
daily cues and learned routines;
housing, relationships, employment and social support; and
the person’s own goals, whether abstinence or an initial reduction in harm.

If GLP-1 medicines eventually enter addiction services, they are more likely to become one tool within this wider work than a stand-alone cure.

The danger of treating yourself

Public enthusiasm has created a market for unregulated products and online claims. Using someone else’s pen, buying an injection without a proper assessment or increasing a prescribed dose to chase a change in cravings can be dangerous.

GLP-1 medicines may cause significant gastrointestinal side effects and dehydration. They are not suitable for everyone, and a clinician needs to consider other medicines and medical conditions. Someone with diabetes who drinks heavily may have additional risks involving blood glucose, nutrition and liver health.

Alcohol withdrawal warning: if you experience morning shaking, sweating, retching, anxiety relieved by drinking, hallucinations or have previously had a withdrawal seizure, do not suddenly stop or sharply reduce alcohol without medical advice. Withdrawal from alcohol dependence can cause seizures, severe confusion and death. Contact a GP or local alcohol service. Call 999 or attend A&E for a seizure, hallucinations, severe agitation or confusion.

A sudden loss of interest in alcohol while taking semaglutide does not remove the risk of withdrawal. Someone who is physically dependent may drink less rapidly because the medicine has changed their appetite, yet their nervous system can still react dangerously to the drop.

What treatments are available in the UK today?

Help with alcohol dependence

A GP or community alcohol service can assess drinking, withdrawal risk, physical health and mental health. Treatment may include a planned medically assisted withdrawal, structured psychological support and relapse-prevention medicines. NICE guidance supports medications such as acamprosate or oral naltrexone with a psychological intervention for suitable people after withdrawal; disulfiram may be considered in selected circumstances.

Services differ across the four nations. In Wales, DAN 24/7 provides confidential alcohol and drug advice. Elsewhere, the NHS website, a GP or local authority service finder can direct people to nearby support. A person living in rural Cornwall may enter care differently from someone near a specialist centre in Liverpool, but both deserve an assessment that is practical and free of judgement.

Help to stop smoking

Proven options include nicotine replacement therapy, commonly combining a patch with a fast-acting product such as gum, lozenges or mouth spray. Nicotine-free medicines—including varenicline, cytisine and bupropion—may be appropriate depending on health history and local availability.

NHS stop-smoking support may be offered through a pharmacy, GP surgery, local clinic, telephone or video service. Treatment plus behavioural support gives a person a better chance than relying on willpower alone. A previous relapse is useful information for planning the next attempt, not evidence that quitting is impossible.

If your cravings change while taking Wegovy or Ozempic

Do not alter your dose. Instead, keep a brief, private record for two or three weeks: how many alcohol units or cigarettes you use, when cravings appear, whether the substance feels different and whether nausea is present. Mention the change to the clinician who prescribed the medicine.

If you want help with drinking or smoking, ask for it directly rather than waiting to see whether the injection does the work. The prescriber may not be an addiction specialist, but they can assess immediate safety and signpost or refer you.

Frequently asked questions

Why does alcohol taste different on semaglutide?

Some people describe altered taste, early fullness or less reward from alcohol. Nausea and slower stomach emptying may also make drinking unpleasant. Research has not established one universal mechanism.

Does Wegovy stop alcohol cravings?

It may reduce craving in some people, and a small semaglutide trial found a significant average reduction. It does not work this way for everyone and is not currently licensed in the UK to treat alcohol dependence.

Can Ozempic help me quit smoking?

There is not enough evidence to recommend Ozempic as a smoking-cessation medicine. Early research suggests a possible reduction in craving, but one small semaglutide trial did not significantly reduce cigarettes smoked per day.

Is Mounjaro being studied for addiction too?

Tirzepatide acts on GIP and GLP-1 receptors and has attracted research interest, but it should not be assumed to have the same effects as semaglutide. Neither should be used as an addiction treatment without appropriate clinical evidence and prescribing.

Will my cravings return if I stop the injection?

We do not yet have adequate long-term addiction data. It is possible that any effect on craving could weaken after treatment stops, which is one reason sustained follow-up and behavioural support are important research questions.

Can I drink alcohol while taking semaglutide?

The NHS advises that it is best not to drink because alcohol may worsen nausea or vomiting. Individual risk also depends on diabetes medicines, liver health, drinking pattern and other conditions. Ask your prescriber for advice specific to you.

A hopeful finding, not a shortcut

The idea that a gut-hormone medicine might quiet the urge to drink or smoke would have sounded improbable not long ago. It now rests on enough laboratory, observational and early clinical evidence to deserve serious attention—including a major new British research effort.

Still, hope is most useful when it is accurate. Semaglutide has not yet been shown to cure alcohol dependence or reliably help people stop smoking. The strongest conclusion in 2026 is that GLP-1 medicines appear to influence reward and craving in some people, and researchers are working out whether that effect can be turned into safe, lasting treatment.

For somebody struggling today, the practical message is simpler: mention any unexpected change in cravings to your prescriber, never risk sudden alcohol withdrawal, and use the effective support that already exists while the science develops.

References and useful UK information

This article provides general health information and does not replace an assessment, diagnosis or treatment from a qualified healthcare professional.